What's New
- A case study of Exemptia in Hidradenitis Suppurativa published in IJDVL Read More..
- A case of relapsing polychondritis with laryngeal stenosis successfully controlled with Exemptia’ accepted in Indian Journal of Rheumatology.
Zydus Innovation Programme is spearheaded by 1200 researchers across 19 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas and concepts to bring in a relentless flow of innovation. In 2013, the group was the first to identify and develop Lipaglyn™ (Saroglitazar) and launch India’s first NCE in the market.
